Science in 2025 is moving fast across nearly every major frontier, from fusion energy breakthroughs to the first CRISPR therapies reaching patients, brain implants restoring digital independence, and telescopes spotting alien atmospheres never seen before. Here’s a look at the most significant developments shaping research and technology right now.
Fusion Energy Hits Record After Record
The National Ignition Facility (NIF) at Lawrence Livermore National Laboratory has now achieved fusion ignition ten times, and the results keep getting more impressive. In April 2025, NIF set a new record by producing 8.6 megajoules of fusion energy from just 2.08 megajoules of laser energy delivered to a tiny target. That’s a target gain of 4.13, meaning the reaction produced more than four times the energy put in. For context, the first ignition experiment in December 2022 produced 3.15 megajoules, so output has nearly tripled in under three years.
The trajectory tells the story. A February 2024 shot yielded 5.2 megajoules. By February 2025, a different configuration reached 5.0 megajoules from a lower-energy laser pulse, setting a new efficiency record. Then came the April result. In June 2025, a team led by Los Alamos National Laboratory achieved ignition using a different approach, creating what’s called a burning plasma: a self-sustaining feedback loop where the fusion reaction heats itself. By October 2025, the facility had logged its tenth ignition.
These are still laboratory-scale experiments, not power plants. The laser system itself consumes far more electricity than it delivers to the target. But each successful shot teaches physicists more about how to reliably trigger and sustain fusion, which is the core challenge standing between these experiments and a future energy source that produces no carbon emissions and minimal radioactive waste.
CRISPR Treatments Reach Patients
Gene editing has crossed from the lab into the clinic. The FDA approved the first CRISPR-based therapy, Casgevy, for sickle cell disease in patients 12 and older. It was approved alongside a second gene therapy called Lyfgenia, which uses a different technique. Both target the same disease: a group of inherited blood disorders affecting roughly 100,000 people in the United States, where abnormally shaped red blood cells block blood flow and cause severe pain crises.
Casgevy works by editing a patient’s own blood stem cells using CRISPR/Cas9, the molecular tool that can cut and modify DNA at precise locations. The edited cells are then infused back into the patient. This represents a fundamentally different approach to treating genetic disease. Rather than managing symptoms for a lifetime, the goal is to fix the underlying genetic problem in a single procedure.
Beyond sickle cell disease, artificial intelligence is accelerating how new drugs are designed in the first place. At least two AI-designed drug candidates have reached Phase 3 clinical trials, the final stage before potential approval. One targets idiopathic pulmonary fibrosis, a progressive lung disease, and was developed by Insilico Medicine using generative AI models. Another, developed by Schrödinger Inc. using deep learning and molecular simulations, is being tested for psoriasis. These represent the first wave of medicines where AI didn’t just assist with data analysis but played a central role in designing the molecule itself.
A Planet With an Atmosphere Nobody Expected
The James Webb Space Telescope continues to rewrite what scientists thought they knew about planets beyond our solar system. One recent observation stood out: a planet orbiting a rapidly spinning neutron star called PSR J2322-2650b, with an atmosphere unlike anything previously recorded. Instead of the usual mix of water vapor, methane, and carbon dioxide that astronomers expect on exoplanets, Webb detected molecular carbon, specifically two- and three-atom carbon chains.
That’s remarkable because carbon at these temperatures (ranging from about 1,200°F on the night side to 3,700°F on the day side) normally binds to whatever other atoms are available. For pure carbon molecules to dominate the atmosphere, there has to be almost no oxygen or nitrogen present. The research team described it as an entirely new category of planetary atmosphere. Soot clouds likely drift through the air, and deeper in the planet, carbon may condense under pressure into diamonds.
Brain Implants Are Getting Faster
Neuralink has now implanted its brain-computer interface in three people. The first recipient, Noland Arbaugh, is paralyzed and uses thin electrode-studded wires in his brain to move a computer cursor, click through menus, browse the web, and play chess, all by thought alone. The company calls this “digital freedom,” and for someone who previously couldn’t interact with a computer independently, that label isn’t hyperbole.
The device’s speed is genuinely impressive. Neuralink reports that Arbaugh reached an information transfer rate of over nine bits per second, which doubled the previous brain-interface record. For comparison, the median score for an able-bodied person using the same measurement is around ten bits per second. The path hasn’t been smooth, though. More than half of the electrode threads in Arbaugh’s brain retracted at one point, degrading his control. The company had to rush software fixes so he could continue using the remaining electrodes. Recalibration is also a daily chore: Arbaugh spends up to 45 minutes doing retraining tasks, like imagining moving a dot around a circle, to keep the system’s neural mapping accurate.
Neuralink plans to implant 20 to 30 more patients during 2025 and has expanded its trials to Canada. A competing company called Synchron is also running human trials with a device that reaches the brain through a blood vessel rather than open surgery. Before any of these devices can be sold commercially, they’ll need to pass a pivotal trial with 20 to 40 patients demonstrating reliable, consistent performance.
The Higgs Boson Reveals a New Trick
At CERN’s Large Hadron Collider, physicists using the ATLAS detector have found compelling evidence that the Higgs boson can decay into muons, a heavier cousin of the electron. This is an extraordinarily rare event, and confirming it matters because it tests whether the Higgs boson gives mass to lighter particles in the way the Standard Model of physics predicts. Using combined data from Run 2 and Run 3 of the LHC, the team measured the signal at 3.4 standard deviations above background noise. In particle physics, 3 standard deviations counts as “evidence” while 5 is the threshold for a confirmed discovery, so more data is needed, but the signal is strong.
The same team also sharpened measurements of another rare decay, where the Higgs boson breaks down into a Z boson and a photon. This particular process is especially interesting because its rate could differ from Standard Model predictions if unknown particles or forces exist. Any deviation would be a signpost pointing toward new physics beyond what current theory describes.
2025 Is on Track as the Second-Warmest Year
The European Union’s Copernicus Climate Change Service reports that 2025 is on course to be the joint-second warmest year on record. Through November, the global average temperature sat 1.48°C above the 1850-1900 pre-industrial baseline. November 2025 alone reached 1.54°C above that baseline, making it the third-warmest November ever recorded.
These numbers matter because 1.5°C is the aspirational limit set by the Paris Agreement. The fact that individual months and near-complete calendar years are now routinely brushing against or exceeding that threshold illustrates how narrow the remaining margin has become. This comes on the heels of 2024, which was influenced by an El Niño event that amplified global temperatures. Even without that boost, 2025 is running almost as hot.
Alzheimer’s Drugs Enter a New Era
A new class of Alzheimer’s treatments targeting the amyloid plaques that build up in the brain is now available, and Medicare covers them, though with conditions. Lecanemab (sold as Leqembi) is FDA-approved and covered by Medicare for people with mild cognitive impairment or mild dementia due to Alzheimer’s disease. To qualify, your doctor must confirm through testing that you have amyloid plaques consistent with Alzheimer’s, and they must enroll you in a qualifying study or registry that tracks how well the drug works over time.
This registry requirement is unusual. It reflects the fact that these drugs, while shown to modestly slow cognitive decline in clinical trials, are still being evaluated for their real-world effectiveness. The treatments work by using lab-made antibodies to clear amyloid protein from the brain. They don’t cure or stop Alzheimer’s, but they represent the first drugs that target a biological cause of the disease rather than just managing symptoms. For patients in the early stages, they offer a genuinely new option that didn’t exist a few years ago.